A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.

Autor: Vormoor, B, Veal, G J, Griffin, M J, Boddy, A V, Irving, J, Minto, L, Case, M, Banerji, U, Swales, K E, Tall, J R, Moore, A S, Toguchi, M, Acton, G, Dyer, K, Schwab, C, Harrison, C J, Grainger, J D, Lancaster, D, Kearns, P, Hargrave, D
Zdroj: Pediatric Blood & Cancer; Dec2016, Vol. 63 Issue 12, pN.PAG-N.PAG, 1p
Databáze: Complementary Index
Externí odkaz: